• Herantis Pharma’s clinical study with Lymfactin advances to high dose level

    March 6, 2017

    Herantis Pharma’s clinical study with Lymfactin advances to high dose level Herantis Pharma PlcCompany release 6 March 2017 at 10:00 am Herantis Pharma Plc’s (“Herantis”) clinical study with the company’s innovative gene therapy investigational product Lymfactin® for the treatment of secondary lymphedema has advanced to highest planned dose level owing to good reported safety. A Data Monitoring Committee of independent experts recommended proceeding to high dose treatments after assessing safety data on the previously treated patients. Following the recommendation, the first high

    Read More
  • miRagen Therapeutics Completes merger with Signal Genetics and Concurrent $40.7M Equity Financing

    February 13, 2017

    BOULDER, CO – February 13, 2017 – Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced the completion of its merger with Signal Genetics, Inc., effective February 13, 2017.  Concurrent with the closing of the merger, miRagen received gross proceeds of $40.7 million in new equity investment from a combination of current and new miRagen investors, including Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd.,

    Read More
  • Nido Surgical Raises $1.3M Series A Led By Broadview Ventures

    February 7, 2017

    Nido Surgical Raises $1.3M Series A Led By Broadview Ventures BOSTON, Feb. 7, 2017 --Nido Surgical, Inc., a development-stage medical device company focused on creating innovative solutions for beating heart surgery, has raised $1.3 million in a Series A financing led by Broadview Ventures (Boston, MA). The funds will be used to finance the development and First-In-Man studies of Nido Surgical' platform product, the CardioPort™. Nido Surgical has also received a $1.4 million Small Business Technology Transfer (STTR) grant from the National Institutes of Health to support this work.

    Read More
  • Remedy Granted Orphan Drug Designation

    January 16, 2017

    Remedy Pharmaceuticals’ CIRARA Granted Orphan Drug Designation For Treatment of Severe Cerebral Edema Caused By Acute Ischemic Stroke NEW YORK, New York, January 17, 2017 — Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatments to people affected by central nervous system related edema, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational drug, CIRARA, for treatment of severe cerebral edema in patients with acute ischemic stroke. Link to Press Release

    Read More